Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy

详细信息    查看全文

• 作者：Juan Zhong^a ; ^b ; ^d ; Wangqiu Gong^b ; Lu Lu^a ; ^b ; Jing Chen^c ; Zibin Lu^a ; HongYu Li^b ; Wenting Liu^b ; Yangyang Liu^a ; ^b ; Mingqing Wang^a ; ^b ; Rong Hu^a ; ^b ; Haibo Long^a ; ^{longhb1966@163.com} ; Lianbo Wei^a ; ^b ; ^{weilianbo@163.com}
• 关键词：Irbesartan ; Hyperlipidemia ; Liver steatosis ; PPAR-γ ; AMPK/Akt/mTOR signaling ; Autophagy
• 刊名：International Immunopharmacology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：42
• 期：Complete
• 页码：176-184
• 全文大小：1562 K
• 卷排序：42

文摘

Irbesartan ameliorates hyperlipidemia and liver steatosis of the db/db mice. The mechanisms that drive the therapeutic effects of irbesartan are proposed. Autophagy plays an important role in the mechanisms of therapeutic effects.